TABLE 2.

Prospective studies on HHV-6 reactivation after SOT

Transplant typeDetection methodbSamplecNo. of patientsIncidence of active HHV-6 infection (%)Observed diseaseeHHV-6 variantReference
HeartPCRPBMC210No disease 298
KidneyPCRPBMC107Not givendNo diseaseNot determined 320
KidneyqPCRPBMC5223No diseaseNot determined 205
KidneyVI, serologyPBMC6555NoneNot determined 455
Kidney and/or liverVI, serologyPBMC3231None (unless concomitant HCMV infection)Not determined 162
Kidney and/or pancreasPCR, serologyUrine, serum3050FeverNot determined 335
LiverIHCLiver tissue, PBMC32Not givenAcute liver failureNot determined 155
LiverIHCPBMC3429HCMV diseaseNot determined 232
LiverqPCRPBMC20028Opportunistic infections, HCMV disease, acute graft rejectionNot determined 171
LiverqPCR, serologyPBMC339HCMV diseaseNot determined 281
LiverqPCRPBMC8854HCMV diseaseNot determined 173
LiverPCR, VI, serologyPlasma4749FeverB 452
LiverVIPBMC8039CNS disease, fungal infectionsNot determined 340
LiverSerology, IHCPBMC5122Graft dysfunctionB 233
LiverqPCRPBMC6032Graft rejectionNot determined 150
LiverSerologySerum24724HCMV diseaseNot determined 108
LiverPCRPBMC46Not givenNone10% A, 90% B 357
LiveraqPCRPBMC6654Increased severity of HCV-related fibrosis or hepatitisNot determined 172
LiveraVIPBMC5141Increased severity of HCV-related fibrosisNot determined 364
Liver heart/lungVI, PCRPBMC, BALF3027Higher mortality rate, fungal infectionsB 192
  • a Study population restricted to hepatitis C virus-positive patients undergoing liver transplantation.

  • b qPCR, quantitative PCR; VI, virus isolation; IHC, immunohistochemistry.

  • c BALF, bronchoalveolar lavage fluid.

  • d Unclear whether PCR was able to discriminate active from latent infection.

  • e HCV, hepatitis C virus.